Literature DB >> 21076159

Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Usman Baber1, Virginia J Howard, Jonathan L Halperin, Elsayed Z Soliman, Xiao Zhang, William McClellan, David G Warnock, Paul Muntner.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is common among patients with end-stage renal disease, but few data are available on its prevalence among adults with chronic kidney disease (CKD) of lesser severity. methods and results: We evaluated the association of CKD with ECG-detected AF among 26 917 participants in the REasons for Geographic and Racial Differences in Stroke (REGARDS) study, a population-based cohort of African-American and white US adults ≥45 years of age. Estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease study equation and albuminuria was defined as a urinary albumin to creatinine ratio ≥30 mg/g. Participants were categorized by renal function: no CKD (eGFR ≥60 mL/min/1.73 m(2) without albuminuria, n=21 081), stage 1 to 2 CKD (eGFR ≥60 mL/min/1.73 m(2) with albuminuria n=2938), stage 3 CKD (eGFR 30 to 59 mL/min/1.73 m(2), n=2683) and stage 4 to 5 CKD (eGFR <30 mL/min/1.73 m(2), n=215). The prevalence of AF among participants without CKD, and with stage 1 to 2, stage 3, and stage 4 to 5 CKD was 1.0%, 2.8%, 2.7% and 4.2%, respectively. Compared with participants without CKD, the age-, race-, and sex-adjusted odds ratios for prevalent AF were 2.67 (95% confidence interval, 2.04 to 3.48), 1.68 (95% confidence interval, 1.26 to 2.24) and 3.52 (95% confidence interval, 1.73 to 7.15) among those with stage 1 to 2, stage 3, and stage 4 to 5 CKD. The association between CKD and prevalent AF remained statistically significant after further multivariable adjustment and was consistent across numerous subgroups.
CONCLUSIONS: Regardless of severity, CKD is associated with an increased prevalence of AF among US adults.

Entities:  

Mesh:

Year:  2010        PMID: 21076159      PMCID: PMC3049935          DOI: 10.1161/CIRCEP.110.957100

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  32 in total

1.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

2.  Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients.

Authors:  Simonetta Genovesi; Daniela Pogliani; Andrea Faini; Maria G Valsecchi; Alessandra Riva; Francesca Stefani; Irene Acquistapace; Andrea Stella; Giuseppe Bonforte; Amedeo DeVecchi; Vincenzo DeCristofaro; Gherardo Buccianti; Antonio Vincenti
Journal:  Am J Kidney Dis       Date:  2005-11       Impact factor: 8.860

3.  C-reactive protein and microalbuminuria are associated with atrial fibrillation.

Authors:  Folkert W Asselbergs; Maarten P van den Berg; Gilles F H Diercks; Wiek H van Gilst; Dirk J van Veldhuisen
Journal:  Int J Cardiol       Date:  2005-01       Impact factor: 4.164

4.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

5.  Cross-sectional association of kidney function with valvular and annular calcification: the Framingham heart study.

Authors:  Caroline S Fox; Martin G Larson; Ramachandran S Vasan; Chao-Yu Guo; Helen Parise; Daniel Levy; Eric P Leip; Christopher J O'donnell; Ralph B D'Agostino; Emelia J Benjamin
Journal:  J Am Soc Nephrol       Date:  2005-12-28       Impact factor: 10.121

6.  Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria.

Authors:  P N Casale; R B Devereux; P Kligfield; R R Eisenberg; D H Miller; B S Chaudhary; M C Phillips
Journal:  J Am Coll Cardiol       Date:  1985-09       Impact factor: 24.094

7.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Authors:  P A Wolf; R D Abbott; W B Kannel
Journal:  Stroke       Date:  1991-08       Impact factor: 7.914

8.  The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study.

Authors:  A D Krahn; J Manfreda; R B Tate; F A Mathewson; T E Cuddy
Journal:  Am J Med       Date:  1995-05       Impact factor: 4.965

9.  Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study.

Authors:  E J Benjamin; D Levy; S M Vaziri; R B D'Agostino; A J Belanger; P A Wolf
Journal:  JAMA       Date:  1994-03-16       Impact factor: 56.272

10.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13
View more
  76 in total

1.  Association of Fibroblast Growth Factor 23 With Atrial Fibrillation in Chronic Kidney Disease, From the Chronic Renal Insufficiency Cohort Study.

Authors:  Rupal Mehta; Xuan Cai; Jungwha Lee; Julia J Scialla; Nisha Bansal; James H Sondheimer; Jing Chen; L Lee Hamm; Ana C Ricardo; Sankar D Navaneethan; Rajat Deo; Mahboob Rahman; Harold I Feldman; Alan S Go; Tamara Isakova; Myles Wolf
Journal:  JAMA Cardiol       Date:  2016-08-01       Impact factor: 14.676

Review 2.  Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Hemal Bhatt; Monika Safford; Stephen Glasser
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

3.  Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.

Authors:  Melissa Kucey; Jennifer Bolt; Lori Albers; Ali Bell; Nkem Iroh; Julie Toppings
Journal:  Can J Hosp Pharm       Date:  2016-10-31

4.  Chronic kidney disease: Safe anticoagulation for patients with CKD--are we there yet?

Authors:  Elsayed Z Soliman
Journal:  Nat Rev Nephrol       Date:  2012-11-13       Impact factor: 28.314

5.  Renal function assessment in atrial fibrillation: Usefulness of chronic kidney disease epidemiology collaboration vs re-expressed 4 variable modification of diet in renal disease.

Authors:  Rami Riziq-Yousef Abumuaileq; Emad Abu-Assi; Andrea López-López; Sergio Raposeiras-Roubin; Moisés Rodríguez-Mañero; Luis Martínez-Sande; Francisco Javier García-Seara; Xesus Alberte Fernandez-López; Jose Ramón González-Juanatey
Journal:  World J Cardiol       Date:  2015-10-26

6.  Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States.

Authors:  Benjamin A Goldstein; Cristina M Arce; Mark A Hlatky; Mintu Turakhia; Soko Setoguchi; Wolfgang C Winkelmayer
Journal:  Circulation       Date:  2012-10-02       Impact factor: 29.690

Review 7.  Dabigatran etexilate: appropriate use in patients with chronic kidney disease and in the elderly patients.

Authors:  Mauro Molteni; Mario Bo; Giovanni Di Minno; Giuseppe Di Pasquale; Simonetta Genovesi; Danilo Toni; Paolo Verdecchia
Journal:  Intern Emerg Med       Date:  2017-04-24       Impact factor: 3.397

Review 8.  Calcium as a cardiovascular toxin in CKD-MBD.

Authors:  Sharon M Moe
Journal:  Bone       Date:  2016-08-27       Impact factor: 4.398

Review 9.  Anticoagulation for atrial fibrillation in patients on dialysis: are the benefits worth the risks?

Authors:  Jenny I Shen; Mintu P Turakhia; Wolfgang C Winkelmayer
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-11       Impact factor: 2.894

Review 10.  Cardiovascular Pharmacogenomics--Implications for Patients With CKD.

Authors:  Larisa H Cavallari; Darius L Mason
Journal:  Adv Chronic Kidney Dis       Date:  2016-03       Impact factor: 3.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.